131 related articles for article (PubMed ID: 29703333)
1. Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP.
Wilcox RA
Lancet Haematol; 2018 May; 5(5):e182-e183. PubMed ID: 29703333
[No Abstract] [Full Text] [Related]
2. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
Oki Y; Younes A; Copeland A; Hagemeister F; Fayad LE; McLaughlin P; Shah J; Fowler N; Romaguera J; Kwak LW; Pro B
Br J Haematol; 2013 Jul; 162(1):138-41. PubMed ID: 23590726
[No Abstract] [Full Text] [Related]
3. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and treatment of peripheral T-cell lymphoma].
Suzumiya J; Moriyama I; Kawakami K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():519-24. PubMed ID: 23134009
[No Abstract] [Full Text] [Related]
5. Beyond CHOP: optimising frontline therapy in peripheral T-cell lymphoma.
Amin F; Gleeson M
Ann Palliat Med; 2022 Jul; 11(7):2548-2552. PubMed ID: 35815455
[No Abstract] [Full Text] [Related]
6. [A case report of composite lymphoma].
Wu J; Wang ZC; Chen XD
Ai Zheng; 2007 Apr; 26(4):447. PubMed ID: 17430672
[No Abstract] [Full Text] [Related]
7. Peripheral T-Cell Lymphoma Presenting as a Primary Uterine Cervix Mass: A Report of a Rare Case.
Kosari F; Niknejad N; Nili F; Jahanbin B; Malek M
Int J Gynecol Pathol; 2017 Nov; 36(6):523-527. PubMed ID: 28244895
[TBL] [Abstract][Full Text] [Related]
8. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
[TBL] [Abstract][Full Text] [Related]
9. Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma.
Quesada AE; Rios A; Brown RE; Nguyen ND
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S87-9. PubMed ID: 25486962
[No Abstract] [Full Text] [Related]
10. Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.
Otrock ZK; Hatoum HA; Salem ZM; Tawil A; Mahfouz RA; Zaatari GS; Bazarbachi A
Ann Hematol; 2008 Dec; 87(12):1023-4. PubMed ID: 18587577
[No Abstract] [Full Text] [Related]
11. The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma.
Ham JS; Kim SJ; Choi JY; Hyun SH; Choi SK; Kim HS; Lim SH; Lee JY; Jung SH; Ko YH; Kim WS
Blood Cancer J; 2016 Feb; 6(2):e395. PubMed ID: 26871713
[No Abstract] [Full Text] [Related]
12. Thoracic subcutaneous infiltration: an unusual presentation of subcutaneous panniculitis-like T-cell lymphoma.
Ballanger F; Barbarot S; Le Gouill S; Gaillard F; Cassagnau E; Lodé L; Dréno B; Stalder JF
Acta Derm Venereol; 2009; 89(4):427-9. PubMed ID: 19688166
[No Abstract] [Full Text] [Related]
13. [Recent advance in peripheral T-cell lymphoma, not otherwise specified].
Duan R; Zhang JZ
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):427-9. PubMed ID: 21055168
[No Abstract] [Full Text] [Related]
14. ECHELON-2 - brentuximab raises PTCL outcomes to new levels.
Killock D
Nat Rev Clin Oncol; 2019 Mar; 16(3):145. PubMed ID: 30602757
[No Abstract] [Full Text] [Related]
15. Rosai Dorfman disease and peripheral T-cell lymphoma: A rare co-occurrence.
Tiwari V; Pareek A; Ghori H; Ahirwar M
J Postgrad Med; 2019; 65(1):62-63. PubMed ID: 30464074
[No Abstract] [Full Text] [Related]
16. [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
Qin Y; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Liu XF; Liu P; Yang S; Zhou LQ; Han XH; Yao JR
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):448-51. PubMed ID: 20819488
[TBL] [Abstract][Full Text] [Related]
17. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Maeda Y; Nishimori H; Yoshida I; Hiramatsu Y; Uno M; Masaki Y; Sunami K; Masunari T; Nawa Y; Yamane H; Gomyo H; Takahashi T; Yano T; Matsuo K; Ohshima K; Nakamura S; Yoshino T; Tanimoto M
Haematologica; 2017 Dec; 102(12):2097-2103. PubMed ID: 28971899
[TBL] [Abstract][Full Text] [Related]
18. [Epstein-Barr virus-positive diffuse large B-cell lymphoma following peripheral T-cell lymphoma, not otherwise specified: report of a case].
Zhang F; Liu YH; Zhuang HG; Li L; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):414-5. PubMed ID: 21055162
[No Abstract] [Full Text] [Related]
19. Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
Jelinek T; Zuchnicka J
Blood; 2020 May; 135(20):1816. PubMed ID: 32407530
[No Abstract] [Full Text] [Related]
20. Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.
Toya T; Nannya Y; Hangaishi A; Shiseki M; Shimoyama T; Sakamaki H; Motoji T; Usuki K; Nakamura F; Kurokawa M
Leuk Lymphoma; 2016; 57(4):961-4. PubMed ID: 26366623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
